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Abstract
Background: UK and US policy initiatives have suggested that, in the future, patients and clinicians in
mainstream medicine could use genetic information to prevent common illnesses. There are no studies on
patients' experience and understanding of the process of testing for common genetic susceptibilities in
mainstream medicine.
Methods: Qualitative interviews with 42 individuals who had undergone testing for a genetic susceptibility
for deep vein thrombosis in primary and secondary care in the UK.
Results: Some participants, often from higher social classes, had a good understanding of the test and its
implications. They had often sought additional information on thrombophilia from relatives and from the
Internet. Others, often from less privileged backgrounds, had a poorer understanding of the test – seven
individuals were unaware of having had the genetic test. Features of genetic information led to
misunderstandings: (i) at referral, (ii) when communicating results, and (iii) when making sense of the
implications of testing. Participants' accounts indicated that non-specialist doctors may feel obliged to refer
a patient for a genetic test they know little about, because a patient requests it after a relative had tested
positive. Sometimes a referral for a genetic test was lost under information overload when multiple tests
and issues were considered. The inconsistent and informal ways of communicating test results – for
example by phone – in mainstream medicine also led to confusion. Participants did not generally
overestimate their risk, but some were uncertain about whether they were taking the right preventive
actions and/or whether their children were at risk. Information about genetic susceptibilities was difficult
to make sense of, as it related to ambiguous risks for participants and family members, complicated and
unfamiliar terminology and multiple genes and preventive strategies.
Conclusion: Policy visions of clinicians and patients in mainstream medicine seeking and using genetic
information at their own initiative may not be realistic. Patients need more direct support in making sense
of genetic information, if this information is to bring the anticipated health benefits, and not fuel health
inequalities or create ethical problems. Clinicians in secondary and primary care need guidance to help
them introduce genetic tests, communicate their results and explain their implications.
Published: 12 June 2007
BMC Health Services Research 2007, 7:82 doi:10.1186/1472-6963-7-82
Received: 28 February 2007
Accepted: 12 June 2007
This article is available from: http://www.biomedcentral.com/1472-6963/7/82
© 2007 Saukko et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Page 1 of 8
(page number not for citation purposes)
BMC Health Services Research 2007, 7:82 http://www.biomedcentral.com/1472-6963/7/82Background
Transformation of genetics
In the early and mid 20th century genetics and genetic
counselling were expected to provide family planning or
contraceptive/sterilization advice to couples in order to
avoid passing on "bad genes" [1]. Later these eugenistic
ideas became suspect. The role of genetic counselling
changed into provision of "non-directive" advice on the
likelihood of inherited disease or disability [2].
As long as genetics was associated with mostly incurable
single-gene disorders it appeared as an ethically conten-
tious matter best managed by clinical genetics. The devel-
opment of preventive strategies for conditions such as
familial hypercholesterolaemia has changed the nature of
genetics. The UK Government's White Paper on Genetics
has suggested that as the science advances, testing for
genetic susceptibilities could, in the future, become a rou-
tine part of primary prevention of common diseases, such
as heart disease, diabetes and cancer [3,4]. There are cur-
rently very few valid genetic tests for susceptibility to com-
mon illnesses, but the US Centers for Disease Control
(CDC) is developing an online tool (Family Healthware)
that would enable people to collect information about
family history of common illness and personal behaviour
and to receive preventive advice online and/or from their
physician [5]. UK policy makers are developing similar
initiatives [6].
The initiatives to incorporate genetic information into
everyday healthcare and into online self-health tools
reflect developments in science and contemporary health
care policies. New policies envision individuals to
become "experts" in preventing disease and "choosing"
health and healthcare [7,8]. Visions of individuals taking
charge of their health promise to democratise medicine
but also shift responsibility for health from professional
services towards the individual [9,10].
Qualitative studies on people's views on being experts in
relation to their health have discovered that some people
feel that "knowing" is the "doctor's job" [11] or resent the
idea of "choosing" best health care, noting it should be
"offered automatically" [12]. Quantitative studies indi-
cate that individuals with less education or lower incomes
or from ethnic minorities are least likely to seek health
information at their own initiative, more likely to place
their trust in doctors and less likely to take preventive
actions [13,14]. Similar inequalities have been observed
in breast cancer genetics; ethnic minorities and people
with a lower socio-economic status are significantly less
likely to seek risk assessment and testing [15].
In short, the ethos in genetics-related health policy is shift-
ing from protecting patients from potentially harmful
information towards enhancing public health through
encouraging clinicians and patients to seek and use infor-
mation about genetic susceptibilities to prevent disease
[16]. In this article we explore how the new ethos works
in practice by examining how patients experience and
understand testing for a genetic susceptibility in routine
clinical practice.
Experiences of testing
Psychological studies have indicated that genetic testing
for single-gene diseases does not generally increase indi-
viduals' anxiety [17,18]. It has been suggested that indi-
viduals who seek genetic testing are already concerned
about their susceptibility to disease, and testing may help
them to cope with stress and uncertainty [19].
With the increasing emphasis on prevention, research has
focused on behavioural effects. Genetic testing has not
been observed to motivate smoking cessation in a com-
munity setting [20] and its effects on cancer screening
behaviour has been contradictory [21]. But a clinic-based
study reported haemochromatosis testing to motivate
venesection, a simple preventive strategy [22].
Many studies have reported shortcomings in lay under-
standing of genetic information. Qualitative studies have
observed that individuals have difficulties in understand-
ing, or accepting, inheritance patterns [23]. People also
adopt various lay models of inheritance, thinking that
they are more likely to inherit a genetic susceptibility from
family members, who are "like" them in terms of phy-
sique or personality [24].
Quantitative studies have observed that, for example,
patients with familial hypercholesterolaemia (FH) have a
poor understanding of risk and inheritance [25]. Yet, in a
FH trial all participants correctly reported their genetic test
results [26]. It has been reported that genetic counselling
enhances understanding of breast cancer genetic knowl-
edge, particularly among the better educated [27]. In a
study investigating the use of genetic tests results in moti-
vating smoking cessation in the community, 45% of low-
income African-Americans did not understand their test
results [20]. A research project on patients' experiences of
testing for predisposition to haemochromatosis (iron
overload) in a clinic-setting found that a third of partici-
pants did not know how many mutations they had inher-
ited [22], and healthy individuals tested for
haemochromatosis were observed to be nonchalant about
the condition in a qualitative study [28]. In the only study
conducted so far on patients' perceptions of genetic test-
ing for thrombophilia in primary and secondary care,
79% of the participants could not correctly approximate
their risk of deep vein thrombosis [29].Page 2 of 8
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not necessarily cause psychological anxiety, but neither
does it necessarily motivate behaviour change. Literature
also indicates that patients' understanding of genetic test-
ing and its implications is often patchy, particularly in
community settings. This partly reflects the fact that non-
specialist doctors in primary and secondary care do not
have a good knowledge of genetics and do not often per-
ceive it as pertinent to their work [30-35].
Recently, guidelines and tools have been produced for
communicating about genetic information [36] and for
evaluating the quality of information provided [37]. Pro-
grammes for training specialist general practitioners and
nurses to support the integration of genetics into primary
care have also been developed [3]. Still, the processes that
guide patients' experiences and understanding of genetic
information in mainstream medicine have not been
examined. This article explores these processes.
Thrombophilia
We chose to focus on patients' experiences of genetic test-
ing for thrombophilia, because it offers a good model for
understanding genetic susceptibility testing. Throm-
bophilia is: (i) common, (ii) associated with low risk, (iii)
can be tested in mainstream medicine, and (iv) people
tested can be offered advice on preventive strategies. The
most common allele associated with the susceptibility,
factor V Leiden (FVL), is present in 1:25 of Caucasians,
and being heterozygous (having inherited the allele from
one parent) for FVL is associated with 0.6% annual risk of
deep vein thrombosis among healthy individuals [38].
Other rarer thrombophilias, such as Antithrombin defi-
ciency, are associated with more significant risk [39].
Thrombophilia is also associated with miscarriage [40].
Preventive strategies include: avoidance of the combined
oral contraceptive and hormone replacement therapy
(HRT); precautions/prophylaxis to be adopted in high risk
situations (surgery, pregnancy and postpartum, long
flights); and avoidance of smoking and weight. Throm-
bophilia can be tested for in primary and secondary care,
without the necessary involvement of clinical genetics
[41,42]. The clinical utility of thrombophilia testing has
been a matter of debate [43]. A recent UK Health Technol-
ogy Assessment report did not recommend throm-
bophilia screening for all women before going on the oral
contraceptive pill, but testing is recommended for indi-
viduals with a personal or family history of deep vein
thrombosis, or a relative with thrombophilia [39].
Although thrombophilia testing receives much less public
attention than breast cancer genetics, it is one of the most
common genetic tests in the US and the UK [29,44].
Methods
We first identified typical situations in which individuals
are referred for factor V Leiden testing, by analysing labo-
ratory requests received by the Royal Devon & Exeter NHS
Foundation Trust Molecular Genetics Laboratory between
April 2002 and March 2004. We used descriptive statistics
to identify patterns of referral in terms of: (i) source of
referral; (ii) gender of patient; (iii) reason for; and (iv) test
results.
The descriptive analysis informed the maximum variation
sampling for a qualitative interview study. We invited a
total of 97 participants for semi-structured interviews via
their referring doctors (general practitioners or consultant
haematologists). We invited participants from both pri-
mary and secondary care, with different reasons for refer-
ral, women and men, with different test results and from
socioeconomically diverse areas. We chose qualitative
methods, because they allow for exploring processes that
lead to quantitative outcomes, such as patients' under-
standing, in the new area of genetic susceptibility testing
in mainstream medicine [45].
After obtaining ethical approval we conducted interviews
with consenting participants between January and
November 2004. Most interviews took place in the partic-
ipant's home. The interviews followed the format of dis-
covery interviews [46]. We asked the respondents to relate
their experience of being tested in a chronological order;
how they came to have the test, why they decided to have
it, how they learnt the results and reacted to them, what
they did with the information afterwards, and what they
thought of the process of testing as a whole. The schedule
provided a naturally flowing chronological structure for
the interviews that covered the process of testing but was
open-ended enough to allow the participants to expand to
other areas they deemed important. The interviews were
recorded and transcribed. They were analysed for themes
using the constant comparative method [47], which
inductively seeks to identify themes that emerge across
cases. The thematic analysis was aided by the NVivo qual-
itative software. The interviews were all conducted and
interpreted by one experienced researcher (PS); a sample
of six interviews was read independently for themes and




Of the 390 referrals (307, 79% women), 190 (49%) orig-
inated from primary and 173 (44%) from secondary care,
27 (7%) originating from outside Devon. The majority
(295, 76%) of individuals tested had normal results,
whilst 94 (24%) were heterozygous and one (0.3%) was
homozygous for FVL. The most common reasons for refer-Page 3 of 8
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(DVT) (115/390, 30%); (ii) family history of DVTs (74/
390, 19%); (iii) family history of genetic thrombophilia
(67/390, 17%); and (iv) recurrent miscarriages (45/390,
11%).
The referral patterns indicated that thrombophilia testing
was adopted by both primary and secondary care clini-
cians, and encompassed both individuals who have had a
DVT, and healthy individuals who have a family history of
thrombophilia or DVTs.
Qualitative themes
Of the 97 individuals invited, 42 consented to interview.
Twenty-five of the 42 participants reported having been
referred to the test because of family history of throm-
bophilia or DVTs, ten were referred because of personal
history of DVTs, 5 were referred for other reasons (such as
miscarriages) and seven were unaware of being tested.
Most of the participants (37/42) were women; 22
belonged to social class I and II, whilst 20 belonged to
social class III, IV and V [48]. Twenty-six individuals with
positive results for a thrombophilia marker (participants
had often been screened for a panel of five markers)
responded to our invitation to participate, but we only
recruited nine participants who had normal results (seven
were unaware of having had the test). The slanting of the
sample towards individuals with thrombophilia should
be borne in mind when interpreting the findings.
One theme that emerged from the interviews was that par-
ticipants did not consider thrombophilia testing special
even if it identified a genetic susceptibility; we have dis-
cussed this theme elsewhere [49]. Another prominent
theme that emerged was that participants' understanding
of the test, its results and implications varied widely. This
article focuses on this diversity in understandings of the
test, exploring processes that lead to better or worse
understanding.
The understanding of the individuals did not fall into
clear categories but lay on a spectrum. Some participants
understood the test well; they knew they had had the test,
recalled its results (including the marker they had inher-
ited) and understood the familial and preventive conse-
quences. Others had a fair or poor understanding of the
test. Some presumed their test results were normal, even
though they could not recall receiving their results. Some
knew they were positive for thrombophilia but did not
know which marker they had inherited even though dif-
ferent markers are associated with differing risks; they
were also unsure about whether or not they were doing
the right things to prevent DVTs. Seven participants were
unaware of having had the genetic test.
The participants who understood the test well derived pre-
dominantly from social class I and II, and participants
with poorer understanding were predominantly from
social class III, IV and V.
Three sub themes emerged from the interviews that
brought into relief the processes that led to differences in
understanding: (i) the referral situation, (ii) receiving and
interpreting results, and (iii) understanding of the risk
and the implications of testing.
The referral situation
Individuals, who understood the test well, sometimes
described the information provided by the doctors as
"comprehensive" (Participant 034); other times they
commented that for their general practitioner "it was actu-
ally the first time she had heard" of factor V Leiden (025).
Well-informed participants, who were referred for the test
based on family history of thrombophilia had often
acquired a basic understanding of thrombophilia prior to
testing from knowledgeable family members. When rela-
tives had provided individuals with reasonably good
information, which was complemented by the doctor's
advice, their understanding of the test at referral was
straightforward, as illustrated by the account of a young,
well-educated woman:
Mum just said that there was a test that me and [my
brother] had to have to see, if we'd got this factor V Leiden.
... And when I went in with Dr H he just told me what it
was. [09]
Sometimes the information provided by relatives had
been less clear, but participants had sought further infor-
mation from the Internet prior to contacting a clinician so
that they "probably knew all that [the doctor] told and
more already" (021). Occasionally the participant had
taken on the collection of information on behalf of the
entire family, particularly in cases where the participant
deemed other family members to have difficulties in
accessing and understanding information. A community
care worker had consulted the Internet on behalf of her
family after her brother tested positive for factor V Leiden
when diagnosed with a DVT, from complications of
which he later died. She also noted that such information
seeking was necessary in the case of thrombophilia but
not in relation to well-understood and supported ill-
nesses, such as diabetes:
We didn't know anything about it, so we sort of just looked
[on the Internet], and basically we did it for everybody else,
you know. Obviously, my mum and dad was concerned
because of [my brother]. ... But no, I don't think [we usu-
ally consult the Internet]...even with Andrew's [partner's
pseudonym] diabetes we've never gone on the Net for that.Page 4 of 8
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We've had loads and loads of information for that. [025]
Less informed participants had also often been referred
for testing on account of a family history of throm-
bophilia or DVTs, but they frequently indicated that their
relatives had not provided them with much background
knowledge. They were more likely than well informed
participants to report that their doctor had not provided
them with good information, saying, for example, that he
"never explained [the test] properly" (030). Others
acknowledged they had trouble understanding informa-
tion, stating that it "went over our head" (023). A middle-
aged male accountant had asked for the test, after his
brother's doctor recommended all family members to be
tested following his DVT; the brother had not told him
much about the condition, and the participant ended up
knowing he was positive but did not know the marker. He
considered that he was provided with little information,
as the doctor presumed he knew about the test as he
requested it:
She [did not explain the test] in so many words because of
the fact that I'd asked for a test myself ... I think that she
assumed that I knew what I was being tested for. And as far
as I am aware it was just a blood test that had to be done
and we went from there [018]
Two of the participants who were unaware of having had
the genetic test had most likely been referred to it in a con-
sultation over prescribing the oral contraceptive or HRT.
There had been a difference in opinion between the clini-
cian and the patient, and the test was probably used to
mediate the difference and was lost under the main issue
of prescribing. Five participants who were unaware of hav-
ing had the genetic test had had several DVTs or cerebrov-
ascular events. They related that they sometimes had to
"insist" on proper medical attention (for example, when
experiencing an acute DVT) (026). Yet, they tended to
trust their doctors the details of their complex care, such
as multiple diagnostic tests, as indicated by the account of
a retired pub-keeper:
I don't remember ever having had the test. ... But I have
had lots of blood tests. But I've never known ... really what
they were doing with it. [015]
Receiving and interpreting results
Participants had learnt of their genetic test results in
inconsistent and sometimes informal ways: during a con-
sultation, in writing, on the phone or they did not recall
receiving the results. Less informed participants were
sometimes confused about the manner in which results
would be communicated to them. In several cases they
had expected their doctor to call them in person, if the
results were positive. In a couple of cases participants
thought their results were normal or that they were "clear"
because the doctor had not contacted them, only to find
out later, when they queried about it, that they "had it"
(023). A couple of participants did not at the time of the
interview recall receiving the results, presuming they were
"fine," as the doctor had not called them (011). One par-
ticipant was referred to the test after recurrent miscarriages
and was given "a negative result when it was positive" by
the receptionist (038). Afterwards she had another mis-
carriage and a daughter who died soon after birth. She
admitted that the cause of the tragedy was uncertain, but
that in her "heart" she believed it all had to do with clot-
ting, and that if the test results had been conveyed cor-
rectly she may have "looked at it a bit closer" during the
subsequent pregnancies (038).
On many occasions the more and less informed partici-
pants had received the test results in identical manner but
reacted to the information differently. After learning their
results the well informed participants often sought addi-
tional information or advice from their doctors and else-
where. This is illustrated by a university lecturer's
description of her initial reaction to learning on the phone
she had inherited factor V Leiden and having been reas-
sured by her doctor not to worry:
I think I rang up for [the results] ... So, I immediately made
an appointment to talk to my doctor about it. ... She looked
at me and she said, "You're not obese and you're not a
smoker. You don't need to worry". And I felt, "Well, don't
just dismiss me" ... [One needs] advice and clarification
about what things you do need to worry about and what
things you don't need to worry about. I think I've sort of
gleaned information by looking at the Internet or talking to
my brother or talking to my father. It just makes me much
more secure, really. [010]
A less informed participant, a young woman working in
the supermarket, was also communicated the test results
over the phone. Yet, rather than pursue further informa-
tion she concluded that the matter was not important as
her doctor had reassured her that she needed to take no
specific actions consequent on the test results:
Eventually someone told me that apparently they weren't
supposed to tell me like that. I was supposed to go in and see
them, but they had just told me [the results] over the phone.
But, mmm, I still didn't go and see the doctor. They didn't
call up for me or nothing ... and my GP had said that I
would just carry on as normal anyway. [027]
Many participants, involving both those with good and
those with poor understanding, stated that they would
have appreciated written information on thrombophiliaPage 5 of 8
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commented that they felt they were not able to "take it all
in" (036) during a consultation.
Understandings of risk and the implications of testing
In the first few interviews patients described themselves as
"not too anxious" (037) or "blasé" (039) about throm-
bophilia. In later interviews we explored this theme sys-
tematically by asking the participants whether they
considered the risk associated with thrombophilia to be
small, medium, or high (this question was not posed
when individuals were unaware of having had the genetic
test). Of the twenty-three interviewees asked this question
only three thought the risk was high, eleven estimated it
as small and nine as medium. The three participants who
considered their risk high all had a poorer general under-
standing of thrombophilia.
Most participants did not recall their doctor explaining
the risk to them; they had "just figured it out" (017), con-
cluded their risk was medium due to family history
("father had it") (010) or gleaned the understanding from
"the way the doctor explained it" (018). Some partici-
pants remembered the doctor relating a numerical risk fig-
ure, such as "1 in 100" (020); one participant recalled the
doctor estimating that the risk was "a lot bigger," but she
did not agree with him, as she had been "healthy" (039).
We have reported elsewhere that participants, who knew
they had thrombophilia, had stopped taking the com-
bined contraceptive pill and hormone replacement ther-
apy but had not changed their lifestyle [49]. There were no
dramatic differences in terms of preventive actions report-
edly taken following communication of test results
between the well and the less well-informed participants,
excluding those who were unaware of being tested.
However, the participants differed in respect of the confi-
dence in their acquired knowledge. A female scientist,
who had experienced a DVT in her early thirties after
going on the pill and had been identified to have inher-
ited factor V Leiden, had requested a referral to a consult-
ant to ask about prevention. Her knowledge was very
detailed and covered all eventualities:
I often have to travel by plane to Rome. [Professor A] told
me that I can, if I want to, have an injection of heparin. He
said, if I feel more comfortable, I can just take half of an
Aspirin. ... And obviously he tried to explain to me how I
can change my life in order to help my circulation and to
help myself keep fit. And then I also asked what of contra-
ception? ... So he said that there are different alternatives.
So, then I went to a clinic in Exeter, and I have a coil now,
so I'm quite happy with it. Then I asked him about preg-
nancy as well. What should I tell to my doctors and what
should I ask them to take care of? And he just said I should
be on heparin, I think in the hospital [03].
A homemaker, who had experienced a DVT during preg-
nancy and been identified to have thrombophilia, was
much less certain about prevention. The participant also
asked the interviewer for advice on prevention:
Oh, yes [the doctor did mention hormones] I'm not allowed
to go on the Pill. ... I just ... do a lot of walking ... But, apart
from that, well, I don't know [what to do to prevent clot-
ting]. I just carry on as day-to-day, and I'm pretty happy
with that. ... I suppose you could tell me the most high risk
factor of it all, because I don't know a lot about it to be hon-
est. [037]
Most of those participants who had had DVTs but were
unaware of having had the test, said they would want to
know, "if it is heritable" to help their children. Some of
them stated they had "suspected" (035) that abnormal
clotting was a hereditary condition. However, their lack of
understanding did not enable them to clarify their suspi-
cions or to inform their children about familial risk:
Yes, [I would like to know if there is a risk in my family]
especially, if it might help my offspring ... Because our elder
daughter has got very big legs. She's always had very sturdy
legs but they ... they could give her problems, I think, later
on. [026]
Discussion
We do not want to argue that genetic information is
always "exceptional" or different from other medical
information, or that patients necessarily perceive it as
such [49]. Some features of genetic information, however,
led to misunderstandings in thrombophilia testing in
mainstream medicine at referral, when receiving and
interpreting results, and when making sense of their risk
or the implications of testing.
Based on our findings genetic information can create an
unusual situation at referral. A non-specialist doctor may
feel obliged to refer a patient for a genetic test they may
know little about, simply because a patient requests it
after a relative has tested positive. Referral for a genetic test
in mainstream medicine may also happen in a complex
clinical context, such as when prescribing or in relation to
an acute or chronic illness involving many diagnostic
tests. In such a situation the genetic test, with its familial
and other specificities, may disappear under information
overload for the patient and/or the clinician.
Our study also indicates that the inconsistent and infor-
mal ways of communicating test results in mainstream
medicine may not be suitable for relaying genetic suscep-Page 6 of 8
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implications for relatives, regardless of whether they are
abnormal or normal. Patients' reports also suggest that cli-
nicians may be concerned about making patients anxious
about a genetic susceptibility and may reassure them in a
manner, which was perceived as uninformative or led to
ignorance and confusion.
Most participants did not recall the doctor explaining
their risk, but they had gleaned a sense of the risk being
low from their family history, which is also reported in
other studies[24], or from the doctor's behaviour. Partici-
pants, who understood the test well, estimated their risk
as small or moderate and were confident about their
knowledge of prevention. Participants with poorer under-
standing occasionally considered their risk to be high;
generally they deemed themselves to be at a low or mod-
erate risk but sometimes fluctuated between nonchalance
and mild worry, such as between being content with lim-
ited knowledge and asking the interviewer questions
about prevention. Such uncertainty may be conducive of
not undertaking preventive actions consistently. Some
participants' accounts suggest that shortcomings in com-
munication and understanding about genetic testing for
thrombophilia can create worries in sensitive areas of life,
such as risks to children or pregnancy. This can fuel feel-
ings of guilt and resentment in the event of a serious med-
ical event, including miscarriage or stillbirth, occurring to
the patient or amongst the wider family.
Recent policy initiatives suggest that, in the future,
patients would actively seek information, possibly online,
about genetic risk factors with a view of preventing com-
mon diseases [5,6]. In the light of our findings these
visions do not seem realistic. Participants had difficulties
understanding genetic information, because it involved
complicated and unfamiliar terminology (such as the
names of the markers), implied uncertain risks for them-
selves and family mebers and was associated with multi-
ple markers and preventive strategies. Participants who
had sought information about thrombophilia at their
own initiative from the Internet or relatives did have a
good understanding of the condition. But many of our
participants, particularly those with lower socioeconomic
status, did not go out their way to pursue health and risk
information at their own initiative; many expected their
doctors to take the lead in explaining the testing process,
its results and risks and to provide them with direct
advice. Similar findings about disadvantaged people's
reluctance to seek information have been reported in rela-
tion to health behaviour in general [13] and in relation to
genetics in particular [15].
The fact that some patients were unaware of having had
the thrombophilia test or had a poor or fair understand-
ing of what was being tested for and its results also com-
promises informed consent. The impact of thrombophilia
testing may be much slighter than in testing for Hunting-
ton's disease, but the classical principle of guaranteeing
patient's consent and informing them of the possible
familial, psychological and social implications of genetic
testing remains of importance.
Conclusion
Recent initiatives have sought to enhance non-specialist
clinicians' ability to use genetic information by providing
communication guidelines [36], tools to evaluate the
quality of information provided [37] and by training
genetics specialist general practitioners and nurses [3].
These initiatives are steps in the right direction. However,
more support for patients and clinicians in mainstream
medicine is needed if the forecast health benefits of pre-
ventive genetics are to be reached without deepening
health inequalities or compromising the ethical integrity
of testing. In particular clinicians need guidance and sup-
port, suitable for mainstream medicine, to help them
introduce genetic susceptibility tests, communicate their
results, preferably in person, and to explain the level of
risk and the implications of test results, complemented
with accessible written information.
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